Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has announced its acquisition of Alcami’s Germantown, Wisconsin facility in the US.
The new facility will further bolster Sterling’s US presence and will provide additional capacity for customer API development and manufacturing projects, specifically those with complex and hazardous requirements.
The Germantown facility houses state-of-the-art cGMP development, scale-up and manufacturing facilities and has specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“We’re delighted to announce our acquisition of the Germantown facility in the US. This is the latest step of our strategic growth plans and will ensure we continue to provide a strong transatlantic API presence to support our customers,” Kevin Cook, CEO of Sterling Pharma Solutions, said. “The US market continues to be a key growth area for us. In addition to bolstering our API clinical and commercial manufacturing the Germantown facility has extensive expertise in handling high potency APIs, which will be a valuable addition to our organisation. We’re excited to welcome the Germantown team into the Sterling family.”
“We want to thank the Germantown leadership team and employees for their dedication to the business and wish them success in the future,” Walt Kaczmarek, Chief Executive Officer of Alcami said. “Alcami has over 40 years of experience providing comprehensive drug product manufacturing and analytical testing services. This transaction continues our strategy to focus investments on our core service offerings.”